DDInter222 DDInter298
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) downregulates {v} (Gene) CCND1
CCND1 {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) upregulates {v} (Gene) HSPA5
HSPA5 {u} (Gene) regulates {v} (Gene) GSTT1
GSTT1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is associated with {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bortezomib {u} (Compound) downregulates {v} (Gene) CCND1
CCND1 {u} (Gene) regulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Bortezomib (Compound) binds SLC31A1 (Gene) and Bortezomib (Compound) upregulates SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Carboplatin (Compound)
Bortezomib (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Bortezomib (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Bortezomib (Compound) downregulates CCND1 (Gene) and CCND1 (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Bortezomib (Compound) upregulates HSPA5 (Gene) and HSPA5 (Gene) regulates GSTT1 (Gene) and GSTT1 (Gene) is bound by Carboplatin (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Carboplatin (Compound)
Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is associated with esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Bortezomib (Compound) downregulates CCND1 (Gene) and CCND1 (Gene) regulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)